The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids encoding the fusion proteins, as well as vectors and cells comprising such nucleic acids.
RELATED APPLICATION
This application claims the benefit of U.S. Provisional Application No. 60/589,678, filed on Jul. 20, 2004, the entire teachings of which are incorporated herein by reference.
